PAH could be explained, at least partially, by Src inhibition, causing inactivation of an important two pore domain potassium channel in pulmonary artery smooth muscle cells (PASMCs; Nagaraj et al., 2013), while dasatinib-induced endothelial dysfunction may be independent of Src inhibition. This evidence concerns the gene SRC and pulmonary arterial hypertension.